Myriad Genetics stock plunges after UnitedHealth Group announces they will no longer cover genetic tests for mental health ...

In a report released yesterday, Daniel Brennan from TD Cowen maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was ...

在充满挑战的市场环境中，Myriad Genetics, Inc. (MYGN)股价触及52周新低，跌至16.6美元。这一最新价格走势反映出过去一年1.15%的温和增长，表明在更广泛的市场波动中经历了一段相对稳定的时期。投资者正密切关注公司的表现，因为股价在52周范围的低端附近波动可能表明对那些希望利用医疗保健板块动态的投资者来说既存在潜在风险也有机会。 在其他近期新闻中，Myriad Genet ...

GeneSight, a Mason-based company specializing in mental health medication, expanded its wellness services in the community.

Myriad Genetics Inc (MYGN) reports robust revenue growth and strategic initiatives despite facing policy changes impacting ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

UnitedHealth (UNH) on Friday disclosed that it would stop covering multi-panel pharmacogenetic tests, including Myriad’s (MYGN) ...

盐湖城 - 专门从事基因测试和精准医疗的Myriad Genetics, Inc. (NASDAQ: MYGN)宣布对联合健康最近的政策更新表示不同意。该保险公司计划从2025年1月1日起，在其商业和个人交换福利计划下限制多基因组药物基因组学测试的覆盖范围，包括Myriad的GeneSight测试。 这一政策变更于周五传达给Myriad，公司对此表示惊讶和失望。Myriad的总裁兼首席执行官Pau ...